Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
about
Prospects for dengue vaccines for travelersThe dengue vaccine pipeline: Implications for the future of dengue controlDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityVaccines and immunization strategies for dengue preventionMapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and VaccinationDengue research opportunities in the AmericasPatterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strainIn a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccinationCurrent progress in dengue vaccinesDengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeysImmune correlates for dengue vaccine developmentUtility, limitations, and future of non-human primates for dengue research and vaccine developmentDengue vaccines: recent developments, ongoing challenges and current candidates.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsA new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialAn alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profilesLong-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultationAnimal models of dengue virus infectionChallenges in reducing dengue burden; diagnostics, control measures and vaccines.Developing a dengue vaccine: progress and future challenges.RNA-based viral vectors.Recent progress in dengue vaccine development.Development of Peptide Vaccines in Dengue.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.Dengue Vaccine: The Need, the Challenges, and Progress.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.Zika Virus Vaccine Development.Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Dengue vaccine development: challenges and emerging opportunities
P2860
Q26314423-7F0FCD22-A428-4F09-97E3-C0662C53527BQ26314683-2262A154-03A1-4325-BBC7-CD5DD7FE2581Q27654848-84D4DDC4-C962-407A-8F38-9AD48DC4E7B0Q28077521-C7B5623B-391E-49A2-A2B2-BD08B3B9C36AQ28114614-1923C1FD-B2BF-4CA1-A375-6EBE6C1BB184Q28656204-D1BB2EEA-9CDD-4965-AC20-4CF246F5BC26Q28729784-1A5EAAD9-8793-4EBB-AE40-92AE8F328184Q30250977-2DB4C4E3-FF70-41FE-9633-9B0CF32E43A7Q33408300-D510F9F8-052C-4800-9AD5-0A0DFA8AFA51Q33800244-AE253AE3-6DF4-4A42-A0BC-0E229742EAE1Q33924674-0ED484B4-5078-41CC-886D-A76B6F534633Q34238916-78EB7118-79BF-4D2D-AADF-C4D1EADCD2F6Q34367194-C5A3F3E0-EFCC-4382-B7FA-ABE52BEBDCD1Q35069160-2D987791-98D0-43E2-B444-20719EA50D10Q35548048-66DE9CDF-7F98-4CE5-B734-18A3FDF5C789Q36181531-11A8476D-B92A-4C7A-9045-CA4DCECFF96DQ36205859-9C4DEDD4-D609-4724-9587-409E8AA885F8Q36607295-FF7BC2C3-2FE5-4C71-AE29-D804FD72548BQ36667964-AF4AB815-0F96-4367-A11C-23B38DEE2F23Q36756643-844A92A2-EDBE-45E9-B7BE-0A62193542D1Q36846290-9E294BCC-4AB3-4202-AFEB-0DF31601CAF1Q37115807-648D5E4D-767B-459E-8611-EEC4763C7C43Q37184768-AFB4901D-62E6-4E15-83F5-6277B789259FQ37706823-B6DAA788-5634-4A88-8808-F634002E6284Q37987131-9A7DBD6C-5C54-4F99-B528-F7519F68F465Q38140035-050B4797-8A24-4DB1-A170-ACF13FBAC356Q38201151-E997D461-DB7E-407A-8AAA-C8FDC3D49624Q38266413-7A84E2C7-48F1-42BF-B5F5-6E21EFB62FD9Q38303232-1499AC9D-6CA2-4B4D-BD60-87807B066607Q40038715-B9AB386F-3AE6-4BE8-B7FB-10E8D4B40BE3Q40109446-F3DF16D4-43C5-4B89-A403-FEFFCF7A775BQ40116968-8731E392-DC66-43C4-97E0-9C722F35988DQ42336350-703B5680-BC80-45F3-89F1-C11863FFD0FBQ42985743-A96927B3-7E5E-4E15-BBC2-59F5A3B20C3AQ45323668-7132FD61-7161-4F1E-84DA-21AE2A23FB61Q47006432-22E6A734-FBEA-407F-8711-4190E6EDCAF7Q47570091-8A1BF083-E9BC-4778-9284-3659EA67286BQ53158319-32EC3D98-EC07-4189-B228-0B2EC52E7B5C
P2860
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Development and clinical evalu ...... uated tetravalent DENV vaccine
@ast
Development and clinical evalu ...... uated tetravalent DENV vaccine
@en
type
label
Development and clinical evalu ...... uated tetravalent DENV vaccine
@ast
Development and clinical evalu ...... uated tetravalent DENV vaccine
@en
prefLabel
Development and clinical evalu ...... uated tetravalent DENV vaccine
@ast
Development and clinical evalu ...... uated tetravalent DENV vaccine
@en
P2093
P2860
P1433
P1476
Development and clinical evalu ...... uated tetravalent DENV vaccine
@en
P2093
Alexander C Schmidt
Beth D Kirkpatrick
Kristen K Pierce
P2860
P304
P356
10.1016/J.VACCINE.2011.07.023
P407
P577
2011-07-21T00:00:00Z